$CKPT
Checkpoint Therapeutics, Inc.

2022 Q2 Form 10-Q Financial Statement

#000141057822002432 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $18.00K $52.00K $16.00K
YoY Change -88.39% -25.71% -46.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.129M $2.243M $2.128M
YoY Change 0.71% -5.36% 0.38%
% of Gross Profit
Research & Development $12.05M $14.67M $27.66M
YoY Change 67.45% 248.21% 239.36%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $14.18M $16.91M $29.79M
YoY Change 52.3% 156.8% 190.03%
Operating Profit -$14.16M -$16.86M
YoY Change 54.68% 158.68%
Interest Expense $22.00K $13.00K $14.00K
YoY Change 69.23% 30.0% -30.0%
% of Operating Profit
Other Income/Expense, Net $22.00K $13.00K
YoY Change 69.23% 0.0%
Pretax Income -$14.14M -$16.85M -$29.76M
YoY Change 54.66% 158.8% 190.87%
Income Tax
% Of Pretax Income
Net Earnings -$14.14M -$16.85M -$29.76M
YoY Change 54.66% 159.0% 190.87%
Net Earnings / Revenue -78566.67% -32400.0% -185975.0%
Basic Earnings Per Share -$0.16 -$0.20
Diluted Earnings Per Share -$0.16 $0.20 -$373.3K
COMMON SHARES
Basic Shares Outstanding 87.51M 85.05M
Diluted Shares Outstanding 87.51M 85.05M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.89M $41.48M $54.74M
YoY Change -52.57% -30.91% 34.25%
Cash & Equivalents $30.90M $41.48M $54.74M
Short-Term Investments
Other Short-Term Assets $18.00K $52.00K $17.00K
YoY Change -88.39% -23.53% -15.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $32.08M $42.91M $55.73M
YoY Change -51.48% -30.15% 30.83%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $32.08M $42.91M $55.73M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $32.08M $42.91M $55.73M
YoY Change -51.48% -30.15% 30.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.58M $9.859M $16.14M
YoY Change 147.63% 179.45% 369.43%
Accrued Expenses $591.0K $339.0K $843.0K
YoY Change 104.5% 111.88% 56.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.62M $22.69M $25.98M
YoY Change 166.2% 212.75% 260.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $24.62M $22.69M $25.98M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $24.62M $22.69M $25.98M
YoY Change 166.2% 212.75% 260.01%
SHAREHOLDERS EQUITY
Retained Earnings -$230.9M -$216.7M -$199.9M
YoY Change 45.4% 44.76% 39.58%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.462M $20.22M $29.75M
YoY Change
Total Liabilities & Shareholders Equity $32.08M $42.91M $55.73M
YoY Change -51.48% -30.15% 30.83%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$14.14M -$16.85M -$29.76M
YoY Change 54.66% 159.0% 190.87%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$11.23M -$19.61M -$9.478M
YoY Change 96.86% 321.0% 92.25%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 642.0K 6.347M 4.010M
YoY Change -94.05% -73.46% 8.97%
NET CHANGE
Cash From Operating Activities -11.23M -19.61M -9.478M
Cash From Investing Activities
Cash From Financing Activities 642.0K 6.347M 4.010M
Net Change In Cash -10.59M -13.26M -5.468M
YoY Change -307.95% -168.84% 337.44%
FREE CASH FLOW
Cash From Operating Activities -$11.23M -$19.61M -$9.478M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87509824
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75492853
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86286655
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
9312000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72912456
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Central Index Key
EntityCentralIndexKey
0001651407
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77574405
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84905751
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38128
dei Entity Registrant Name
EntityRegistrantName
CHECKPOINT THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2568632
dei Entity Address Address Line1
EntityAddressAddressLine1
95 Sawyer Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02453
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652-4500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CKPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30887000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54735000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1178000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
976000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
18000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
17000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
32083000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
55728000
CY2022Q2 us-gaap Assets
Assets
32083000
CY2021Q4 us-gaap Assets
Assets
55728000
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23496000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
24919000
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1125000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1063000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
24621000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25982000
CY2022Q2 us-gaap Liabilities
Liabilities
24621000
us-gaap Operating Expenses
OperatingExpenses
31095000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87509824
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4372000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4487000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
14182000
CY2021Q4 us-gaap Liabilities
Liabilities
25982000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84905751
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77574405
CY2022Q2 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
0
CY2021Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
2121422
CY2021Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
6598000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
238305000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
223001000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230852000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199862000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7462000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
29746000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32083000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55728000
CY2022Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
18000
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
155000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
70000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
223000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12053000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7198000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26723000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11411000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2129000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2114000
us-gaap Operating Expenses
OperatingExpenses
15898000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14164000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9157000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31025000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15675000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
22000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
us-gaap Investment Income Interest
InvestmentIncomeInterest
35000
us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14142000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9144000
us-gaap Net Income Loss
NetIncomeLoss
-30990000
us-gaap Net Income Loss
NetIncomeLoss
-15649000
us-gaap Net Income Loss
NetIncomeLoss
-15649000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75492853
us-gaap Share Based Compensation
ShareBasedCompensation
1504000
us-gaap Share Based Compensation
ShareBasedCompensation
1540000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
213000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
887000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Net Income Loss
NetIncomeLoss
-30990000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86286655
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72912456
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
20216000
CY2022Q2 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
642000
CY2022Q2 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
17000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
729000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14142000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7462000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
29746000
ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
8687000
ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
213000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1504000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1698000
us-gaap Net Income Loss
NetIncomeLoss
-30990000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7462000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
54175000
CY2021Q2 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
10824000
CY2021Q2 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
253000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
766000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9144000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
56874000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
34717000
ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
887000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1540000
us-gaap Net Income Loss
NetIncomeLoss
-15649000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
56874000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
202000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-960000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
135000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1361000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2032000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30837000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10365000
ckpt Proceeds From Issuance Of Common Stock For At Market Offering
ProceedsFromIssuanceOfCommonStockForAtMarketOffering
8910000
ckpt Proceeds From Issuance Of Common Stock For At Market Offering
ProceedsFromIssuanceOfCommonStockForAtMarketOffering
35614000
ckpt Payment Of Stock Offering Costs
PaymentOfStockOfferingCosts
223000
ckpt Payment Of Stock Offering Costs
PaymentOfStockOfferingCosts
897000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1698000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6989000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34717000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23848000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24352000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54735000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40772000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30887000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65124000
us-gaap Stock Issued1
StockIssued1
6598000
us-gaap Stock Issued1
StockIssued1
4617000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230900000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2015Q1 ckpt Equity Method Investment Annual Equity Fee Percentage
EquityMethodInvestmentAnnualEquityFeePercentage
0.025
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4205698
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4560392
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0065
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.0065
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0271
CY2021Q2 ckpt Common Stock Increase In Shares Authorized
CommonStockIncreaseInSharesAuthorized
40000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 ckpt Shelf Registration Statement Maximum Authorized Securities
ShelfRegistrationStatementMaximumAuthorizedSecurities
100000000
CY2022Q2 ckpt Shelf Registration Statement Remaining Authorized Securities
ShelfRegistrationStatementRemainingAuthorizedSecurities
45700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0130
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0104
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0150
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23496000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
24919000
CY2022Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
729000
CY2021Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
766000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1504000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1540000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12582000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16139000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
591000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
843000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9974000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7704000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
349000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
233000

Files In Submission

Name View Source Status
0001410578-22-002432-index-headers.html Edgar Link pending
0001410578-22-002432-index.html Edgar Link pending
0001410578-22-002432.txt Edgar Link pending
0001410578-22-002432-xbrl.zip Edgar Link pending
ckpt-20220630.xsd Edgar Link pending
ckpt-20220630x10q.htm Edgar Link pending
ckpt-20220630xex31d1.htm Edgar Link pending
ckpt-20220630xex31d2.htm Edgar Link pending
ckpt-20220630xex32d1.htm Edgar Link pending
ckpt-20220630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ckpt-20220630_cal.xml Edgar Link unprocessable
ckpt-20220630_def.xml Edgar Link unprocessable
ckpt-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ckpt-20220630_pre.xml Edgar Link unprocessable
ckpt-20220630x10q_htm.xml Edgar Link completed